title: Oxidative damage of the gastric mucosa in Helicobacter pylori positive chronic atrophic and nonatrophic gastritis, before and after eradication.
abstract: BACKGROUND
  Helicobacter pylori is the main cause of gastritis and a primary carcinogen. The aim of this study was to assess oxidative damage in mucosal compartments of gastric mucosa in H. pylori positive and negative atrophic and nonatrophic gastritis.
  
  
  METHODS
  Five groups of 10 patients each were identified according to H. pylori positive or negative chronic atrophic (Hp-CAG and CAG, respectively) and nonatrophic gastritis (Hp-CG and CG, respectively), and H. pylori negative normal mucosa (controls). Oxidative damage was evaluated by nitrotyrosine immunohistochemistry in the whole mucosa and in each compartment at baseline and at 2 and 12 months after eradication. Types of intestinal metaplasia were classified by histochemistry.
  
  
  RESULTS
  Total nitrotyrosine levels appeared significantly higher in H. pylori positive than in negative patients, and in Hp-CAG than in Hp-CG (p <.001); no differences were found between H. pylori negative gastritis and normal mucosa. Nitrotyrosine were found in foveolae and intestinal metaplasia only in Hp-CAG. At 12 months after H. pylori eradication, total nitrotyrosine levels showed a trend toward a decrease in Hp-CG and decreased significantly in Hp-CAG (p =.002), disappearing from the foveolae (p =.002), but remaining unchanged in intestinal metaplasia. Type I and II of intestinal metaplasia were present with the same prevalence in Hp-CAG and CAG, and did not change after H. pylori eradication.
  
  
  CONCLUSIONS
  Oxidative damage of the gastric mucosa increases from Hp-CG to Hp-CAG, involving the foveolae and intestinal metaplasia. H. pylori eradication induces a complete healing of foveolae but not of intestinal metaplasia, reducing the overall oxidative damage in the mucosa.
authors.affiliation: Gastroenterology Unit, Department of Clinical Sciences, University La Sapienza of Rome, Italy.
authors.forename: Federico
authors.initials: F
authors.lastname: Iacopini
authors.forename: Adriana
authors.initials: A
authors.lastname: Consolazio
authors.forename: Daniela
authors.initials: D
authors.lastname: Bosco
authors.forename: Adriana
authors.initials: A
authors.lastname: Marcheggiano
authors.forename: Antonino
authors.initials: A
authors.lastname: Bella
authors.forename: Roberta
authors.initials: R
authors.lastname: Pica
authors.forename: Omero A
authors.initials: OA
authors.lastname: Paoluzi
authors.forename: Pietro
authors.initials: P
authors.lastname: Crispino
authors.forename: Margherita
authors.initials: M
authors.lastname: Rivera
authors.forename: Marcella
authors.initials: M
authors.lastname: Mottolese
authors.forename: Francesco
authors.initials: F
authors.lastname: Nardi
authors.forename: Paolo
authors.initials: P
authors.lastname: Paoluzi
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005753:Gastric Mucosa / Q000737:chemistry / Q000382:microbiology / Q000473:pathology*; D005756:Gastritis / Q000378:metabolism / Q000382:microbiology* / Q000473:pathology*; D005757:Gastritis, Atrophic / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000378:metabolism / Q000382:microbiology / Q000473:pathology*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008679:Metaplasia; D008875:Middle Aged; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000032:analysis / Q000276:immunology
chemical_list: C002744:3-nitrotyrosine; D014443:Tyrosine